Program
regorafenib
Also written as “Regorafenib (Stivarga, BAY73-4506)”, “Regorafenib” and “Regorafenib (BAY73-4506)”.
Its studies are mostly in Colorectal Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Pancreatic Neoplasms · Gastrointestinal Stromal Tumors, led by 2 companies.
Drug pageRegorafenib: every studyAll 173 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 321 open or running | phase 4since May 24, 2018 | Apr 17, 2008 | Apr 27, 2028phase 2 · NCT06246643 |
| Sarah Cannon Research Institute | 10 open or running | phase 2since Apr 21, 2015 | Apr 21, 2015 | none ahead |
Also a collaborator on its studies: Novartis, Merck, Bristol-Myers Squibb and Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sarah Cannon Research Institute only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 21, 2015First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT02425683 · 24 enrolled · United States
TargetBeta
“Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule
Studies
The one study Sarah Cannon Research Institute leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02425683Colorectal Neoplasms · United States | 2 | Terminated | Sep 21, 2017 | 24 |
How it is read
Names in the registry
- “Regorafenib (Stivarga, BAY73-4506)”, 21 entries
- “Regorafenib”, 6 entries
- “Regorafenib (BAY73-4506)”, 4 entries
- “TAS-102, Regorafenib , Fruquintinib”, 1 entry
- “Regorafenib, (Stivarga, BAY73-4506)”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 15 studies
- Neoplasms, 10 studies
- Carcinoma, Hepatocellular, 5 studies
- Pancreatic Neoplasms, 1 study
- Gastrointestinal Stromal Tumors, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.